Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Johnson, Michael E ^a   Mahoney, J Matthew ^a   Taroni, Jaclyn ^a   Sargent, Jennifer L ^a   Marmarelis, Eleni ^a   Wu, Ming Ru ^a   Varga, John ^b   Hinchcliff, Monique E ^b   Whitfield, Michael L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLATELET DERIVED GROWTH FACTOR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FIBROBLAST; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MORPHEA; SIGNAL TRANSDUCTION; SKIN BIOPSY; SYSTEMIC SCLEROSIS; CASE CONTROL STUDY; CLINICAL TRIAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; MALE; METABOLISM; MULTICENTER STUDY; PATHOLOGY;

CASE-CONTROL STUDIES; FEMALE; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; MALE; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

EID: 84935081357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114017     Document Type: Article

References (70)

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202. PMID: 3361530
2. Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, et al. (2012) Intrinsic Gene Expression Subsets of Diffuse Cutaneous Systemic Sclerosis Are Stable in Serial Skin Biopsies. J Invest Dermatol 132:1363-1373. doi: 10.1038/jid.2011.472 PMID: 22318389
3. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, et al. (2009) A TGFβ-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 130:694-705. doi: 10.1038/jid.2009.318 PMID: 19812599
4. Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, et al. (2012) Interspecies Comparison of Human and Murine Scleroderma Reveals IL-13 and CCL2 as Disease Subset-Specific Targets. Am J Path 180:1080-1094. doi: 10.1016/j.ajpath.2011.11.024 PMID: 22245215
5. Chung L, Fiorentino D, Ben Barak M, Adler A, Mariano M, et al. (2009) Molecular Framework for Response to Imatinib Mesylate in Systemic Sclerosis. Arth Rheum 60:584-591. doi: 10.1002/art.24221 PMID: 19180499
6. Milano A, Pendergrass SA, Sargent JL, George LK, McCalmont TH, et al. (2008) Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin. PLoS ONE 3:e2696. PMID: 18648520
7. Hinchcliff M, Huang C-C, Wood TA, Mahoney JM, Martyanov V, et al. (2013) Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis. J Invest Dermatol.
8. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8:118-127. PMID: 16632515
9. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406:747-752. PMID: 10963602
10. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. PNAS 95:14863-14868. PMID: 9843981
11. Saldanha AJ (2004) Java Treeview-extensible visualization of microarray data. Bioinformatics 20:3246-3248. PMID: 15180930
12. -ΔΔCT Method. Methods 25:402-408. PMID: 11846609
13. Rubins KH, Hensley LE, Relman DA, Brown PO (2011) Stunned silence: gene expression programs in human cells infected with monkeypox or vaccinia virus. PLoS ONE 6:e15615. PMID: 21267444
14. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98:10869-10874.
15. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, et al. (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. PNAS 100:12319-12324. PMID: 14530402
16. Gardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M, et al. (2006) Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arth Rheum 54:1961-1973. PMID: 16736506
17. Huang LS, Berdyshev E, Mathew B, Fu P, Gorshkova IA, et al. (2013) Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis. FASEB J. doi: 10.1096/fj.12-219634 PMID: 23315259
18. Donati C, Marseglia G, Magi A, Serratì S, Cencetti F, et al. (2011) Sphingosine 1-Phosphate Induces Differentiation of Mesoangioblasts towards Smooth Muscle. A Role for GATA6. PLoS ONE 6:e20389. doi: 10.1371/journal.pone.0020389 PMID: 21629665
19. Pandolfi A, Florita M, Altomare G, Pigatto P, Donati MB, et al. Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis; 1989. Royal Society of Medicine. pp. 1-4.
20. Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, et al. (1995) Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22:1876-1883. PMID: 8991985
21. Iwayama T, Olson LE (2013) Involvement of PDGF in Fibrosis and Scleroderma: Recent Insights from Animal Models and Potential Therapeutic Opportunities. Curr Rheumatol Reports 15:1-6. doi: 10. 1007/s11926-012-0304-0 PMID: 23307576
22. Olson LE, Soriano P (2009) Increased PDGFRα Activation Disrupts Connective Tissue Development and Drives Systemic Fibrosis. Dev Cell 16:303-313.
23. Olson LE, Soriano P (2011) PDGFRβ signaling regulates mural cell plasticity and inhibits fat development. Dev Cell 20:815-826.
24. Wei J, Bhattacharyya S, Varga J (2010) Peroxisome proliferator-activated receptor gamma: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol 22:671-676. doi: 10.1097/BOR.0b013e32833de1a7 PMID: 20693905
25. Wei J, Ghosh AK, Sargent JL, Komura K, Wu M, et al. (2010) PPARγ downregulation by TGFβ in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS ONE 5:e13778.
26. Ghosh AK, Bhattacharyya S, Lakos G, Chen S-J, Mori Y, et al. (2004) Disruption of transforming growth factor β signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor γ. Arth Rheum 50:1305-1318.
27. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, et al. (2009) Peroxisome proliferator-activated receptor-γ abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 23:2968-2977.
28. Bode C, Gräler MH (2012) Immune regulation by sphingosine 1-phosphate and its receptors. Arch Immunol Ther Exper 60:3-12. PMID: 22159476
29. Bu S, Asano Y, Bujor A, Highland K, Hant F, et al. (2010) Dihydrosphingosine 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels. Arth Rheum 62:2117-2126. doi: 10.1002/art.27463 PMID: 20309867
30. Assassi S, Mayes MD, Arnett FC, Gourh P, Agarwal SK, et al. (2010) Systemic sclerosis and lupus: Points in an interferon-mediated continuum. Arth Rheum 62:589-598. doi: 10.1002/art.27224 PMID: 20112391
31. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. PNAS 100:2610-2615. PMID: 12604793
32. Tompkins WA (1999) Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res 19:817-828. PMID: 10476925
33. Chu W-M (2013) Tumor necrosis factor. Cancer Letters 328:222-225.
34. Choubey D, Moudgil KD (2011) Interferons in autoimmune and inflammatory diseases: regulation and roles. J Interferon Cytokine Res 31:857-865. PMID: 22149411
35. Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, et al. (2002) Stereotyped and specific gene expression programs in human innate immune responses to bacteria. PNAS 99:972-977. PMID: 11805339
36. Diehn M, Alizadeh AA, Rando OJ, Liu CL, Stankunas K, et al. (2002) Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Sci Signaling 99:11796. PMID: 12195013
37. Steinman L (2007) A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage. Nature Med 13:139-145. PMID: 17290272
38. Hamidi A, von Bulow V, Hamidi R, Winssinger N, Barluenga S, et al. (2012) Polyubiquitination of Transforming Growth Factor β (TGFβ)-associated Kinase 1 Mediates Nuclear Factor-κB Activation in Response to Different Inflammatory Stimuli. J Biol Chem 287:123-133.
39. Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, et al. (2008) TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exper Cell Res 314:2725-2738. doi: 10.1016/j.yexcr.2008.06.006 PMID: 18586026
40. Farina GA, York MR, Di Marzio M, Collins CA, Meller S, et al. (2010) Poly (I: C) drives type I IFN- and TGFβ-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol 130:2583-2593. doi: 10.1038/jid.2010.200 PMID: 20613770
41. O'Reilly S (2014) Innate immunity in systemic sclerosis pathogenesis. Clin Sci 126:329-337.
42. Atamas SP, White B (2003) Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 14:537-550. PMID: 14563355
43. Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H (2009) Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Experimental Dermatol 18:727-729. doi: 10.1111/j.1600-0625.2008.00828.x PMID: 19320738
44. Homer RJ, Herzog EL (2010) Recent advances in pulmonary fibrosis: implications for scleroderma. Curr Opin Rheumatol 22:683-689. doi: 10.1097/BOR.0b013e32833ddcc9 PMID: 20693906
45. Pechkovsky DV, Prasse A, Kollert F, Engel KM, Dentler J, et al. (2010) Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin Immunol 137:89-101. doi: 10.1016/j.clim.2010.06.017 PMID: 20674506
46. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, et al. (2010) Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Laboratory Invest 90:812-823. doi: 10.1038/labinvest.2010.73 PMID: 20404807
47. Nakayama W, Jinnin M, Makino K, Kajihara I, Makino T, et al. (2012) Serum levels of soluble CD163 in patients with systemic sclerosis. Rheumatol International 32:403-407. PMID: 21120485
48. Mathian A, Parizot C, Dorgham K, Trad S, Arnaud L, et al. (2012) Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. Ann Rheum Dis 71:1227-1234. doi: 10.1136/annrheumdis-2011-200709 PMID: 22696687
49. Murata M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, et al. (2008) Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease? J Dermatol Sci 50:240-242. PMID: 18329249
50. Radstake TR, van Bon L, Broen J, Hussiani A, Hesselstrand R, et al. (2009) The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFβ and IFNγ distinguishes SSc phenotypes. PLoS ONE 4:e5903. doi: 10.1371/journal.pone.0005903 PMID: 19536281
51. Rodríguez-Reyna TS, Furuzawa-Carballeda J, Cabiedes J, Fajardo-Hermosillo LD, Martínez-Reyes C, et al. (2012) Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatology international 32:2653-2660.
52. Deleuran B, Abraham DJ (2007) Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheum 3:682-683.
53. Axtell RC, Raman C (2012) Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 248:23-35. doi: 10.1111/j.1600-065X.2012.01131.x PMID: 22725952
54. Brand S (2009) Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58:1152-1167.
55. Camporeale A (2012) IL-6, IL-17, and STAT3: a holy trinity in auto-immunity? Front Biosci 17:2306-2326. PMID: 22652781
56. Kimura A, Kishimoto T (2011) Th17 cells in inflammation. Int Immunopharmacol 11:319-322.
57. Trojanowska M (2008) Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology 47:v2-v4. PMID: 18784131
58. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, et al. (1995) Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatol 21:1003-1010. PMID: 7705772
59. Black CM, Silman AJ, Herrick AI, Denton CP, Wilson H, et al. (1999) Interferon-α does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, doubleblind, placebo-controlled trial. Arth Rheum 42:299-305.
60. Hinz B (2009) Tissue stiffness, latent TGF-β1 activation, and mechanical signal transduction: implications for the pathogenesis and treatment of fibrosis. Curr Rheumatol Reports 11:120-126.
61. Gerber EE, Gallo EM, Fontana SC, Davis EC, Wigley FM, et al. (2013) Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. Nature 503:126-130. doi: 10.1038/nature12614 PMID: 24107997
62. Brown XQ, Bartolak-Suki E, Williams C, Walker ML, Weaver VM, et al. (2010) Effect of substrate stiffness and PDGF on the behavior of vascular smooth muscle cells: implications for atherosclerosis. J Cell Physiol 225:115-122. doi: 10.1002/jcp. 22202 PMID: 20648629
63. Falanga V, Gerhardt CO, Dasch JR, Takehara K, Ksander GA (1992) Skin distribution and differential expression of transforming growth factor β1 and β2. J Dermatol Sci 3:131-136. PMID: 1498091
64. Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulos G, et al. (1993) Immunohistological demonstration of transforming growth factor-β isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 69:199-204. PMID: 8403557
65. Gay S, Jones RE, Huang G-q, Gay RE (1989) Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 92:301-303. PMID: 2918236
66. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24:328-332. PMID: 9034992
67. Wu M, Assassi S (2013) The role of type 1 interferon in systemic sclerosis. Front Immunol 4. PMID: 24046769
68. Tokumura A, Carbone LD, Yoshioka Y, Morishige J, Kikuchi M, et al. (2009) Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 6:168. PMID: 19521548
69. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM (1997) Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arth Rheum 40:743-751. PMID: 9125259
70. Truchetet M-E, Brembilla NC, Montanari E, Allanore Y, Chizzolini C (2011) Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arth Res Ther 13:R166. doi: 10.1186/ar3486 PMID: 21996293